<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYDROXYCHLOROQUINE SULFATE</span><br/>(hye-drox-ee-klor'oh-kwin)<br/><span class="topboxtradename">Plaquenil Sulfate<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antimalarial</span><br/><b>Prototype: </b>Chloroquine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Derivative closely related to chloroquine. Antimalarial activity is believed to be based on ability to form complexes with
         DNA of parasite, thereby inhibiting replication and transcription to RNA and DNA synthesis of the parasite.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>of the parasite. Effective against <i>Plasmodium vivax</i> and <i>Plasmodium malariae</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Suppressive prophylaxis and treatment of acute malarial attacks due to all forms of susceptible malaria. Used adjunctively
         with primaquine for eradication of <i>Plasmodium vivax</i> and <i>Plasmodium malariae</i>. More commonly prescribed than chloroquine for treatment of rheumatoid arthritis and lupus erythematosus (usually in conjunction
         with salicylate or corticosteroid therapy).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Porphyria cutanea tarda.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to, or retinal or visual field changes associated with quinoline compounds; psoriasis, porphyria, long-term
         therapy in children; pregnancy (category C). Safe use in juvenile arthritis or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic disease; alcoholism, use with hepatotoxic drugs; impaired renal function; metabolic acidosis; patients with tendency
         to dermatitis.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td>
<p>
                  				Note: Doses are expressed in terms of hydroxychloroquine base: 400-mg tablet = 310-mg base; 800-mg tablet = 620-mg base
                  			
               </p><span class="indicationtitle">Acute Malaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 620-mg base followed by 310-mg base at 6, 18, and 24 h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 10-mg base/kg, then 5-mg base/kg at 6, 18, and 24 h<br/><br/><span class="indicationtitle">Malaria Suppression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 310-mg base the same day each week starting 2 wk before exposure and continuing for 46 wk after leaving the area of
               exposure<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 5-mg base/kg the same day each week starting 2 wk before exposure and continuing for 48 wk after leaving the area of
               exposure<br/><br/><span class="indicationtitle">Lupus Erythematosus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 310-mg base 12 times/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 35 mg/kg/d in 12 divided doses (max: 400 mg/d or 7 mg/kg/d)<br/><br/><span class="indicationtitle">Rheumatoid Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400600 mg/d until response, then decrease to lowest maintenance levels possible<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 35 mg/kg/d in 12 divided doses (max: 400 mg/d or 7 mg/kg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug with meals or milk to reduce incidence of GI distress.</li>
<li>Give antacids and laxatives at least 4 h before or after hydroxychloroquine.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Fatigue, vertigo, headache, mood or mental changes, anxiety, <span class="speceff-common">retinopathy,</span> blurred vision, difficulty focusing. <span class="typehead">GI:</span> Anorexia, nausea, vomiting, diarrhea, abdominal cramps, weight loss. <span class="typehead">Hematologic:</span> Hemolysis in patients with G6PD deficiency, <span class="speceff-life">agranulocytosis</span> (rare), <span class="speceff-life">aplastic anemia</span> (rare), thrombocytopenia. <span class="typehead">Skin:</span> Bleaching or loss of hair, unusual pigmentation (blue-black) of skin or inside mouth, skin rash, itching. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aluminum</b>- and <b>magnesium</b>-containing <span class="classification">antacids</span> and <span class="classification">laxatives</span> decrease hydroxychloroquine absorption; separate administrations by at least 4 h; hydroxychloroquine may interfere with response
      to <b>rabies vaccine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and almost completely absorbed. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Widely distributed; concentrates in lungs, liver, erythrocytes, eyes, skin, and kidneys; crosses placenta. <span class="typehead">Metabolism:</span> Partially metabolized in liver to active metabolite. <span class="typehead">Elimination:</span> Eliminated in urine; excreted in breast milk. <span class="typehead">Half-Life:</span> 70120 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness; may not appear for several weeks, and maximal benefit may not occur for 6 mo.</li>
<li>Do baseline and periodic ophthalmoscopic examinations and blood cell counts on all patients on long-term therapy.</li>
<li>Discontinue drug if weakness, visual symptoms, hearing loss, unusual bleeding, bruising, or skin eruptions occur.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn about adverse effects and their symptoms when taking prolonged therapy.</li>
<li>Follow drug regimen exactly as prescribed by the physician.</li>
<li>Make sure to keep this drug out of reach of children.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>